Introduction
The decision to move forward with 3 clinical trials of interleukin-1 (IL-1) blockade for the treatment of acute Kawasaki disease (KD) is a case study in translational science. These trials were born, on the one hand, from transcriptome studies of host response during the acute disease coupled with animal model investigations of key immune signaling pathways and, on the other hand, out of clinical desperation to enhance treatment of patients with severe inflammation in the setting of acute KD. The convergence of laboratory science and clinical observations led to the clinical trials described herein and serves as a model for how such observations can be translated into new therapies.
The successful translation of bench research into clinical practice requires physician scientists who understand both unmet clinical needs and experimental gaps in knowledge. In the case of KD, a self-limited vasculitis of unknown etiology and the most common cause of acquired heart disease in children, communication between research teams achieved the necessary coalescence of science and clinical medicine to rapidly translate experimental mouse data and human transcriptomic data into 3 separate clinical trials on 2 continents. What follows is a story of how research teams in Europe and the US capitalized on experimental findings to devise clinical trials to test a new paradigm: KD is a systemic inflammatory condition in which activation of the IL-1 signaling pathway is an essential driver of disease pathogenesis.
The current understanding of KD is that an immunologic reaction is elicited in genetically susceptible hosts upon exposure to the KD trigger or triggers, which are thought to be stimuli that enter through the upper respiratory tract (1) . Both mystery and controversy surround the exact nature of the trigger, with some groups advocating a novel virus and others suggesting an antigenic exposure without an infectious agent. The subset of children with KD who have damage to the coronary arterial wall (2) (3) (4) and aneurysms in these vessels comprise only 25% of the total population of KD-susceptible children (5) . Therapy with intravenous immunoglobulin (IVIG) reduces the prevalence of aneurysms to 3-6%, and rates of aneurysms are highest among patients who do not become afebrile after the first dose of 2 gm/kg of IVIG (6, 7) .
The mechanism by which IVIG reduces inflammation in the majority of patients is only now being elucidated despite the widespread clinical use of this treatment for more than 3 decades. In vitro studies have documented that IVIG increases IL-1 receptor antagonist (IL1Ra) expression in human monocytes, which may be relevant in KD (8) . Recent immunologic studies have established that secretion of IL-10 by tolerogenic myeloid dendritic cells (MDCs) and natural Treg (nTreg) cells is a critical event in down-regulation of inflammation in acute KD (9, 10) . Incubation of peripheral blood mononuclear cells (PBMCs) with the constant region of the IgG molecule (Fc) in vitro leads to the expansion of a population of Fc-specific nTreg cells and MDCs and to increased secretion of IL-10. Immune monitoring of patients at the subacute stage has established that these populations expand after IVIG treatment in vivo (10) . However, patients who develop coronary artery aneurysms have a reduced capacity to expand these populations due to mechanisms that are currently under study. Other mechanisms of action of IVIG in KD that lead to the very rapid down-regulation of systemic signs of inflammation have yet to be elucidated (11) . Clinicians who care for patients with acute KD have been aware of the need for adjunctive therapies that could be used with IVIG to reduce inflammation in the subsets of patients with early aneurysms, severe myocarditis, and in those who had persistent fever following IVIG infusion.
Role of tumor necrosis factor (TNF) in acute KD
The proinflammatory cytokine TNF was known to be markedly elevated during the acute phase of KD, and levels were highest in patients who developed coronary artery aneurysms (12) . Thus, it was a logical choice to try TNF inhibition with infliximab following the approval of this monoclonal antibody for pediatric patients with inflammatory bowel disease in 2006. After reports of the compassionate use of infliximab for IVIG-resistant KD patients, the results of the first proof-of-concept trial were published in 2008 (13) (14) (15) (16) . This trial enrolled 24 subjects with acute KD who had persistent fever 36 hours after completion of their IVIG infusion and randomized them to either a second IVIG infusion or infliximab at 5 mg/kg. The results were promising, with 11 of the 12 subjects randomized to infliximab becoming afebrile and not requiring further treatment compared with 8 of the 12 subjects who received a second infusion of IVIG. There was no adverse outcome signal, and the pharmacokinetics (PK) of the antibody appeared to be similar to those in adult studies. However, clinicians realized that waiting to initiate additional treatment until a therapy had failed left the patient with unchecked inflammation for a prolonged period and put the coronary arteries at risk from ongoing destructive processes. The shift in interest then focused on intensification of initial IVIG therapy to bring inflammation under control more rapidly.
Clinical trials of intensification of initial therapy
Three sentinel trials that attempted to identify adjuvant therapies that could benefit KD patients took place in the US and Japan. In the Pediatric Heart Network trial of a placebo-controlled, randomized study of a single IV dose of methylprednisolone (30 mg/kg) plus standard therapy (IVIG plus aspirin), no difference was seen in the coronary artery outcome or rate of resistance to IVIG (17) . In the Japanese Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE) study, KD patients at greatest risk of resistance to IVIG and of coronary artery aneurysms were selected using a clinical scoring system that had been validated in the Japanese population but that had shown poor predictive performance for US multiethnic KD patients (7, 18, 19) . Japanese subjects were randomized to either IV methylprednisolone (2 mg/kg) followed by oral methylprednisolone (2 mg/kg) or placebo in addition to IVIG and aspirin and were treated with study drug for ;3-5 weeks. Results showed a significant reduction in resistance to IVIG and in coronary artery Z score (internal diameter of the coronary artery normalized for body surface area and expressed as SDs from the mean) between the groups in favor of steroids.
In a US trial of intensification of initial therapy with TNF blockade, unselected KD patients were randomized to a single dose of infliximab (5 mg/kg) or placebo in addition to IVIG and aspirin (20) . Results showed a significant reduction in measures of inflammation, coronary artery Z score, and duration of fever. However, addition of infliximab to initial IVIG therapy failed to prevent resistance to IVIG. Current evidence supports the use of infliximab as rescue therapy for patients with resistance to IVIG, but trials have not evaluated its use as adjunctive therapy in patients with early evidence of coronary artery damage (21) . Although some benefit was demonstrated in each of these trials, there remained highly IVIG-resistant KD patients whose course was not altered by either steroids or TNF blockade and whose arteries underwent progressive damage despite timely treatment. Thus, clinicians were aware of an unmet clinical need to devise specific and more effective therapies for this subset of patients.
IL-1 as a master cytokine
IL-1 is a central mediator of innate immunity and inflammation and is considered a master cytokine of local and systemic inflammation (22) . IL-1a and IL-1b are encoded by distinct genes, bind to the same receptor (IL-1RI), and have similar biologic properties. IL-1b mediates unchecked inflammation in many autoinflammatory diseases (23) . IL-1b also enhances antigen-driven CD81 T cell differentiation, proliferation, memory, and migration into tissues (24) . This is important with respect to the pathogenesis of acute KD, as CD81 T cells infiltrate the coronary artery wall and likely contribute to a destructive process associated with aneurysm formation (25) .
IL-1b is transcribed as an inactive precursor that requires assembly of the NLRP3 inflammasome to activate caspase 1, the enzyme that cleaves proIL-1b to release the biologically active form of the cytokine. In contrast, the IL1a precursor is functional, and when it is released from necrotic cells at a site of injury it can bind to IL-1RI of neighboring cells, thus initiating a cascade of inflammatory cytokines and chemokines (26) . Circulating IL-1a is rarely detected in patient sera but is found within endothelial cells and apoptotic bodies released from these cells (27) .
The relative contributions of IL-1a and IL-1b to the vasculitis of KD have yet to be defined. It is intriguing that IL-1b signaling prolongs neutrophil survival and drives proliferation of smooth muscle cells (SMCs) and myofibroblast formation (28) (29) (30) (31) , all of which are pathologic hallmarks of the arteriopathy seen in KD (32, 33) . IL-1-induced SMC proliferation is driven by matrix metalloproteinases (MMPs), including MMP-3 and MMP-9, both of which are implicated in KD in humans (30, (34) (35) (36) (37) (38) . Indeed, SMCderived myofibroblasts can actively proliferate in an uncontrolled manner in the arterial wall after KD, leading to luminal myofibroblast proliferation (LMP), which can progress to life-threatening coronary artery stenosis and infarction (39) . Although therapies are available to reduce risk of thrombosis in coronary artery aneurysm, no therapies have been tested to reduce LMP, which can lead to myocardial ischemia. IL-1a signaling may be responsible for amplifying inflammatory cell infiltration into the arterial wall in regions of vascular SMC and endothelial cell necrosis.
Experience with IL-1 blockade in pediatric inflammatory diseases
Cryopyrin-associated periodic syndrome (CAPS) is the only disease for which the use of anakinra in infants (age $8 months and weighing $10 kg) has been approved by both the Food and Drug Administration and the European Medicines Agency, but anakinra is widely used off-label in systemic autoinflammatory and autoimmune syndromes in children, including systemic juvenile idiopathic arthritis (JIA), macrophage activation syndrome, colchicineresistant familial Mediterranean fever and idiopathic pericarditis, and TNF receptor-associated periodic syndrome (40) (41) (42) (43) (44) . In a recent study of 26 patients with the autoinflammatory syndrome neonatal-onset multisystem inflammatory disease, treatment with anakinra for 36 months had a low adverse event rate, with upper respiratory tract infection as the most commonly reported complication (45) . A similar study using anakinra in another CAPS phenotype, MuckleWells syndrome, did not demonstrate any serious adverse events in the 12 patients treated with anakinra, of whom 5 were children (46) . In most of these studies in young children, the dosage of anakinra needed to achieve complete antiinflammatory effect was 4-10 mg/kg/day.
Canakinumab is a selective monoclonal antibody against IL-1b with a long half-life of 22 days (47) (49) . In systemic JIA, the approved dose is 4 mg/kg every 4 weeks (50) .
Specific inhibitors of IL-1a have not been tested in pediatric inflammatory diseases. It is intriguing that a human antibody specific for IL-1a, MABp1, is now in early clinical trials for different advanced cancers in adults and has improved survival and well-being of patients (51) . The availability of selective IL-1-blocking agents will further our understanding of the relative roles of IL-1a and IL-1b in different diseases involving both local and systemic inflammation.
Insights from KD genetic studies
Genetic studies have identified several risk alleles that influence both susceptibility to KD and development of coronary artery aneurysms (52) . Among these, a functional polymorphism in the inositol 1,4,5-trisphosphate 3-kinase C (ITPKC) gene was reproducibly associated with KD susceptibility and coronary artery aneurysms across diverse populations (53) (54) (55) (56) . Another polymorphism that influenced KD susceptibility was only found in the Japanese population and was located in the ORAI1 gene, which encodes for a calcium channel (57) . Importantly, both the ITPKC and ORAI1 genes regulate calcium flux in the cell, and these polymorphisms lead to sustained elevation of intracellular Ca 21 , which can induce both NLRP3 inflammasome activation and secretion of biologically active IL1b as well as release of IL-1a (58-61).
Insights from KD proteomic and transcriptomic studies
Several observations suggested that IL-1 plays an important role in KD vasculitis. The IL-1 pathway is upregulated in children with KD compared to pediatric febrile controls, as demonstrated by increased transcript abundance 270 BURNS ET AL by microarray and by increased levels of pathway proteins in the plasma (62) (63) (64) (65) (66) . Early studies determined that IVIG treatment was associated with a reduction in IL-1b secretion by PBMCs from KD patients with no coronary artery aneurysms as compared to persistently elevated levels in IVIG-treated patients with coronary artery aneurysms (63) . In a microarray study of paired acute and convalescent whole blood samples collected in PAXgene tubes from 146 KD subjects, transcript abundance profiles were compared among pediatric subjects with different acute infectious diseases and pediatric healthy controls (65) . Differentially expressed transcripts were analyzed according to their participation in different biologic pathways. Common features of the top 3 pathways for KD were the abundance of transcripts related to the NLRP3 inflammasome, IL-1a and IL-1b, and caspase 1. The up-regulation of key genes in the IL-1 pathway was confirmed using quantitative reverse transcriptionpolymerase chain reaction in an independent cohort of 20 KD patients and 10 healthy controls (65) . In a different microarray study, IVIG-resistant KD patients, when compared to IVIG-responsive patients, had increased expression of IL-1RI, IL-1RII, IL-1R-associated kinase 3, and TIFA and decreased expression of IL-1Ra (66) .
Insights from the KD vasculitis mouse model
The scarcity of KD tissues obtained at autopsy or heart transplant has limited our studies of the pathophysiology of KD, thus increasing the value of a murine model that recapitulates many of the features of the human disease. A well-described mouse model of coronary arteritis closely mimics the important histologic and immune pathologic features of the cardiovascular lesions of acute KD (67) (68) (69) . A single intraperitoneal injection of Lactobacillus casei cell wall extract (LCWE) reproducibly induces proximal coronary arteritis that is histologically similar to the coronary arteritis observed in KD in humans. In the LCWE mouse model, a subacute coronary arteritis with LMP and stenosis mimics the lesions found in human arteries (70) .
The mouse model of KD vasculitis is also associated with systemic inflammation and increased body temperature. Intact Toll-like receptor 2 and IL-1R signaling via myeloid differentiation factor 88 is required for this LCWE-induced vasculitis (71, 72) . Moreover, this KD mouse model also predicts efficacy of treatment in children with KD. Currently used treatments in humans such as IVIG and anti-TNF antibodies have been shown to be beneficial in preventing coronary arteritis and aortitis in the LCWE-induced KD vasculitis mouse model (73, 74) .
Lee and colleagues demonstrated the key role of IL-1 signaling pathways in the LCWE-induced mouse vasculitis model (75) . Anakinra also prevented LCWEinduced abdominal aortic dilatation and aneurysms (76) . Interestingly, anakinra was even more effective than IVIG or TNF blockade in reducing LCWE-induced myocarditis, and it improved heart function (ejection fraction) measured using small-animal magnetic resonance imaging (70, 72) . Thus, genetic and transcriptomic data from KD patients and data from the experimental mouse model of KD vasculitis have converged on the likely role of IL-1 signaling in the pathogenesis of KD vasculitis ( Figure 1) .
As the use of IL-1 blockade became more widespread for control of a diverse array of inflammatory conditions, clinicians were emboldened to try IL-1 blockade in the treatment of desperately ill KD patients. In the first report of such use, Cohen and colleagues reported treatment of an infant with uncontrolled inflammation and giant aneurysms who finally responded to IL-1 blockade with anakinra after multiple other antiinflammatory therapies had failed (77) . The patient experienced dramatic clinical improvement but required prolonged treatment with anakinra. Subsequently, another patient with severe KD who was resistant to IVIG treatment was treated with anakinra, which was well-tolerated and associated with resolution of systemic and coronary artery inflammation (78) . Thus, a convergence of genetic and genomic studies with experimental animal data and clinical data in humans set the stage for further investigation. The body of evidence supporting the importance of the IL-1 pathway in KD pathogenesis was now compelling enough for the launch of 3 different clinical trials of IL-1 blockade for treatment of acute KD.
Pediatric trials of IL-1 blockade in acute Kawasaki disease
Currently, 3 clinical trials of IL-1 blockade are enrolling patients with KD in Western Europe and the US (Table 1) .
Kawakinra trial (Europe). The Kawakinra trial (European Clinical Trials no. 2014-002715-41) is a phase IIa, single-dose, multicenter trial of anakinra in Europe. The primary objective is to assess the efficacy and safety of anakinra in patients with IVIG-resistant KD. The secondary objective is to assess the effect of anakinra on disease activity, the coronary Z score, and changes in gene expression and protein levels of biomarkers of inflammation. Eligible patients are those ages 8 months (weighing $10 kg) to 18 years with a diagnosis of acute KD according to American Heart Association (AHA) criteria (79) and who have persistent or recrudescent fever at least 48 hours after the initiation of the IVIG infusion. After parental informed consent, subjects enter the screening period between the fourth and thirteenth days of fever. Subjects IL-1 BLOCKADE FOR TREATMENT OF KD Figure 1 . Schematic of vasculitis in acute Kawasaki disease and potential roles of interleukin-1a (IL-1a) and IL-1b in disease pathogenesis. In the inflamed artery, endothelial cells (ECs; blue spindle-shaped cells) and vascular smooth muscle cells (SMCs) transition to myofibroblasts (pink spindle-shaped cells) that secrete matrix metalloproteinases (MMPs) and disordered collagen (blue lines). Polymorphonuclear neutrophils (PMNs) recruited to the media secrete neutrophil elastases (NEs), resulting in breaks in the internal elastic lamina (IEL) and external elastic lamina (EEL). Mononuclear cells trafficking into the media from the lumen and vasa vasorum secrete IL-1b. ECs and SMCs undergoing necrosis release IL-1a. The structural integrity of the arterial wall is diminished, and hydrostatic pressure results in aneurysm formation.
enter the treatment phase if they develop recrudescent fever, and they receive a first dose of 2 mg/kg of anakinra subcutaneously. In case of fever persistence or recrudescence within 24 hours after the first dose, the next dose is increased to 4 mg/kg. Persistence or recrudescence of fever within 24 hours is followed by a further dose increase to 6 mg/kg. If a subject's fever does not respond to a dose of 6 mg/kg within 48 hours, alternative treatment is administered at the discretion of the center's principal investigator. The highest daily dose of anakinra (2-6 mg/kg) is continued to complete 14 days of treatment.
AnakiNrA for KawasakI Disease (ANAKID) trial (US). The ANAKID trial is a phase I/IIa doseescalation study to determine the safety, tolerability, and PK of anakinra in acute KD (ClinicalTrials.gov identifier: NCT02179853) (80) . Study-eligible subjects are KD patients meeting AHA criteria who are within the first 20 days after fever onset, are at least 8 months old, and have a Z score $3.0 for the right coronary artery and/or the left anterior descending coronary artery. All subjects will receive at least 2 weeks of therapy. Only subjects with an echocardiogram at 2 weeks that shows either a right coronary artery or left anterior descending coronary artery Z score $2.5 or an aneurysm ($1.53 the lumen diameter of the adjacent segment) of one of the coronary arteries will complete a 6-week course of anakinra. All subjects will continue in the study for the full 6 weeks whether or not they are receiving anakinra.
Canakinumab trial (Europe). The Canakinumab trial is an industry-sponsored, phase II multicenter trial in 7 countries that is open for enrollment. The trial has 2 treatment arms and will enroll not only IVIG-resistant subjects but also treatment-naive subjects with complete KD diagnosed early in the course of their disease who will receive canakinumab as initial monotherapy. Treatmentnaive subjects will receive a single 6 mg/kg IV dose of canakinumab. The primary outcome measure will be the presence or absence of fever after drug administration. Subjects who respond with complete fever resolution will not receive IVIG and may be selected to receive 1 or 2 follow-up subcutaneous injections at 4 and 8 weeks depending on their C-reactive protein level and clinical followup. Subjects who remain febrile 48-72 hours after the initial canakinumab dose will receive the standard dose of 2 gm/kg of IVIG.
A second canakinumab treatment arm will enroll IVIG-resistant subjects with KD who did not become afebrile following 1 or 2 IVIG infusions. Subjects in this treatment arm will receive the same initial IV dose of canakinumab and second and third doses of canakinumab 4 weeks and 8 weeks after their initial study treatment.
Conclusions
The convergence of human genetic and transcriptomic data from KD patients with animal experimental data from the LCWE-induced mouse model of KD has led to 3 phase I/II clinical trials that should rapidly determine the safety and tolerability of IL-1 blockade in the treatment of KD. The simultaneous testing of different entrance criteria (persistent fever, coronary artery aneurysms, or uncomplicated treatment-naive KD), different end points (body temperature, coronary artery status by echocardiography), and different study medications (anakinra, canakinumab) will accelerate our understanding of the role of IL-1a and IL-1b in KD pathogenesis and the benefits and risks of IL-1 blockade in these diverse study populations.
